St Lukas Clinic, Solingen, Germany
Clinical Epigenetics, the official journal of the Clinical Epigenetics Society, is an open access, peer-reviewed journal that encompasses all aspects of epigenetic principles and mechanisms in relation to human disease, diagnosis and therapy. Clinical trials and research in disease model organisms are particularly welcome. The journal is divided into the following sections:
- Aging, development, imprinting and reproductive epigenetics
- Allergy, immunology, pathogens and inflammation
- Cancer epigenetics and diagnostics
- Cardiovascular epigenetics
- Endocrinology and metabolic disease
- Epigenetic therapy and clinical trials
- Innovative epigenetics therapies
- Neurology and psychiatry
- Nutritional and environmental epigenetics
- All other subjects
For more information on the the section aims and scope visit our sections information page.
Professor Ulrich Mahlknecht studied medicine at the University of Bochum (Germany), the University of Birmingham (UK), the University of Paris (France) and the University of Tübingen (Germany), where he received his medical doctorate in 1995. From 1996 until 1999, Ulrich Mahlknecht was a graduate student at the Picower Graduate School of Molecular Medicine (State University of New York), where he received his PhD degree and where he was then employed as a postdoc and later as the senior scientist. He received his postgraduate medical training in internal medicine at the University of Freiburg in Germany. From 1999 until 2003 he received specialist training in internal medicine and hematology/oncology at the Goethe University in Frankfurt, where he became an assistant professor of internal medicine. From 2004 until 2007 he was an associate professor at the University Hospital in Heidelberg where he was the head of the acute leukemias and myelodysplastic syndromes task force. Ulrich Mahlknecht was the founder of the Heidelberg excellence center for myelodysplastic syndromes. He has actively published in cancer, immunology and HIV research, authoring several classic papers.
Professor Mahlknecht was a scholar within a Deutsche Forschungsgemeinschaft young investigator excellence research program (Emmy Noether-Program). His research was later also supported by the Deutsche José Carreras Leukemia Foundation.
In 2007, he became a full professor of medicine at the Saarland University and head of the Division of Immunotherapy and Gene Therapy within the Department of Internal Medicine. He is now currently Head of the Department of Hematology/Oncology at St. Lukas Clinic in Solingen, Germany. Ulrich Mahlknecht is president of the Clinical Epigenetics Society (CLEPSO), a non-profit international organization, which supports basic, translational and clinical research within the field of epigenetics.
His research currently focuses on novel targeted immunological and epigenetic concepts in the treatment of solid tumors and hematological malignancies.